
Sign up to save your podcasts
Or


For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.
The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.
Disclosure information is available at the beginning of the video presentation.
By PVI, PeerView Institute for Medical Education4
1010 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/XRT865. CME/NCPD credit will be available until April 25, 2026.
The Good, the Bad, and the GVHD: Leveraging Modern Therapeutics to Improve Post-Transplant Outcomes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Incyte Corporation, Mallinckrodt Pharmaceuticals, and Mesoblast Inc.
Disclosure information is available at the beginning of the video presentation.

139 Listeners

318 Listeners

499 Listeners

40 Listeners

27 Listeners

10 Listeners

5 Listeners

10 Listeners

3 Listeners

2 Listeners

5 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

0 Listeners

9 Listeners

2 Listeners

118 Listeners

2 Listeners

4 Listeners

58 Listeners

3 Listeners

5 Listeners

3,348 Listeners

43 Listeners

22 Listeners

2 Listeners

363 Listeners

54 Listeners

58 Listeners

189 Listeners